Development and validation of a staging system for HPV-related oropharyngeal cancer by the International Collaboration on Oropharyngeal cancer Network for Staging (ICON-S): a … B O'Sullivan, SH Huang, J Su, AS Garden, EM Sturgis, K Dahlstrom, ... The Lancet Oncology 17 (4), 440-451, 2016 | 761 | 2016 |
Improved clinical outcomes with high-dose image guided radiotherapy compared with non-IGRT for the treatment of clinically localized prostate cancer MJ Zelefsky, M Kollmeier, B Cox, A Fidaleo, D Sperling, X Pei, B Carver, ... International Journal of Radiation Oncology* Biology* Physics 84 (1), 125-129, 2012 | 594 | 2012 |
Long-term survival and toxicity in patients treated with high-dose intensity modulated radiation therapy for localized prostate cancer DE Spratt, X Pei, J Yamada, MA Kollmeier, B Cox, MJ Zelefsky International Journal of Radiation Oncology* Biology* Physics 85 (3), 686-692, 2013 | 299 | 2013 |
Ten‐year outcomes of high‐dose, intensity‐modulated radiotherapy for localized prostate cancer ZA Alicikus, Y Yamada, Z Zhang, X Pei, M Hunt, M Kollmeier, B Cox, ... Cancer 117 (7), 1429-1437, 2011 | 262 | 2011 |
Tumor control outcomes after hypofractionated and single-dose stereotactic image-guided intensity-modulated radiotherapy for extracranial metastases from renal cell carcinoma MJ Zelefsky, C Greco, R Motzer, JM Magsanoc, X Pei, M Lovelock, ... International Journal of Radiation Oncology* Biology* Physics 82 (5), 1744-1748, 2012 | 227 | 2012 |
Dose escalation for prostate cancer radiotherapy: predictors of long-term biochemical tumor control and distant metastases–free survival outcomes MJ Zelefsky, X Pei, JF Chou, M Schechter, M Kollmeier, B Cox, Y Yamada, ... European urology 60 (6), 1133-1139, 2011 | 225 | 2011 |
Metformin and prostate cancer: reduced development of castration-resistant disease and prostate cancer mortality DE Spratt, C Zhang, ZS Zumsteg, X Pei, Z Zhang, MJ Zelefsky European urology 63 (4), 709-716, 2013 | 209 | 2013 |
The natural history and predictors of outcome following biochemical relapse in the dose escalation era for prostate cancer patients undergoing definitive external beam radiotherapy ZS Zumsteg, DE Spratt, PB Romesser, X Pei, Z Zhang, W Polkinghorn, ... European urology 67 (6), 1009-1016, 2015 | 203 | 2015 |
Patterns of treatment failure and postrecurrence outcomes among patients with locally advanced head and neck squamous cell carcinoma after chemoradiotherapy using modern … JE Leeman, J Li, X Pei, P Venigalla, ZS Zumsteg, E Katsoulakis, ... JAMA oncology 3 (11), 1487-1494, 2017 | 182 | 2017 |
Genomic methods identify homologous recombination deficiency in pancreas adenocarcinoma and optimize treatment selection W Park, J Chen, JF Chou, AM Varghese, KH Yu, W Wong, M Capanu, ... Clinical Cancer Research 26 (13), 3239-3247, 2020 | 165 | 2020 |
Comparison of high‐dose (86.4 G y) IMRT vs combined brachytherapy plus IMRT for intermediate‐risk prostate cancer DE Spratt, ZS Zumsteg, P Ghadjar, MA Kollmeier, X Pei, G Cohen, ... BJU international 114 (3), 360-367, 2014 | 165 | 2014 |
Improved toxicity profile following high-dose postprostatectomy salvage radiation therapy with intensity-modulated radiation therapy A Goenka, JM Magsanoc, X Pei, M Schechter, M Kollmeier, B Cox, ... European urology 60 (6), 1142-1148, 2011 | 148 | 2011 |
AG protein/cAMP signal cascade is required for axonal convergence into olfactory glomeruli AT Chesler, DJ Zou, CE Le Pichon, ZA Peterlin, GA Matthews, X Pei, ... Proceedings of the National Academy of Sciences 104 (3), 1039-1044, 2007 | 143 | 2007 |
Mutations in BRCA1 and BRCA2 differentially affect the tumor microenvironment and response to checkpoint blockade immunotherapy RM Samstein, C Krishna, X Ma, X Pei, KW Lee, V Makarov, F Kuo, ... Nature cancer 1 (12), 1188-1203, 2020 | 139 | 2020 |
Absence of adenylyl cyclase 3 perturbs peripheral olfactory projections in mice DJ Zou, AT Chesler, CE Le Pichon, A Kuznetsov, X Pei, EL Hwang, ... Journal of Neuroscience 27 (25), 6675-6683, 2007 | 125 | 2007 |
A Phase II study of salvage high-dose-rate brachytherapy for the treatment of locally recurrent prostate cancer after definitive external beam radiotherapy Y Yamada, MA Kollmeier, X Pei, CC Kan, NC Gil'ad, SM Donat, BW Cox, ... Brachytherapy 13 (2), 111-116, 2014 | 124 | 2014 |
Precision radiotherapy: reduction in radiation for oropharyngeal cancer in the 30 ROC trial N Riaz, E Sherman, X Pei, H Schöder, M Grkovski, R Paudyal, N Katabi, ... JNCI: Journal of the National Cancer Institute 113 (6), 742-751, 2021 | 122 | 2021 |
Incidence of secondary cancer development after high-dose intensity-modulated radiotherapy and image-guided brachytherapy for the treatment of localized prostate cancer MJ Zelefsky, DM Housman, X Pei, Z Alicikus, JM Magsanoc, LT Dauer, ... International Journal of Radiation Oncology* Biology* Physics 83 (3), 953-959, 2012 | 114 | 2012 |
Comparison of tumor control and toxicity outcomes of high-dose intensity-modulated radiotherapy and brachytherapy for patients with favorable risk prostate cancer MJ Zelefsky, Y Yamada, X Pei, M Hunt, G Cohen, Z Zhang, M Zaider Urology 77 (4), 986-990, 2011 | 112 | 2011 |
Long-term outcomes after high-dose postprostatectomy salvage radiation treatment A Goenka, JM Magsanoc, X Pei, M Schechter, M Kollmeier, B Cox, ... International Journal of Radiation Oncology* Biology* Physics 84 (1), 112-118, 2012 | 110 | 2012 |